Free Trial

Enliven Therapeutics (ELVN) Insider Trading & Ownership

$21.47
-0.91 (-4.07%)
(As of 09/17/2024 ET)

Enliven Therapeutics (NASDAQ:ELVN) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
29.20%
Number Of
Insiders Buying
(Last 12 Months)
0
Number Of
Insiders Selling
(Last 12 Months)
10
Amount Of
Insider Selling
(Last 12 Months)
$44.70 M
Get ELVN Insider Trade Alerts

Want to know when executives and insiders are buying or selling Enliven Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

ELVN Insider Buying and Selling by Quarter

Enliven Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/29/2024Joseph P LyssikatosInsiderSell12,000$22.49$269,880.00  
8/27/2024Benjamin HohlCFOSell4,250$22.54$95,795.00  
8/26/2024Samuel KintzCEOSell12,000$22.89$274,680.00  
8/15/2024Richard A HeymanDirectorSell1,270$23.25$29,527.50  
7/31/2024Benjamin HohlCFOSell991$27.53$27,282.23  
7/31/2024Joseph P LyssikatosInsiderSell3,099$27.56$85,408.44  
Big News: How the Upcoming Rate Cut and Elon Musk’s AI Could Transform Your Investments (Ad)

The Federal Reserve is almost certainly about to cut interest rates, and history tells us that stocks often rally after such moves. In fact, based on my calculations, in seven out of nine rate-cut cycles since 1981, stocks have surged, delivering an average of 36.3% returns over two years. But that's not all... This time, there's another massive trigger on the horizon – Elon Musk's groundbreaking AI technology.

Click here to learn how you can take advantage of these two monumental shifts right now.
7/31/2024Richard A HeymanDirectorSell1,702$27.51$46,822.02  
7/31/2024Samuel KintzCEOSell2,270$27.56$62,561.20  
7/29/2024Benjamin HohlCFOSell5,250$26.68$140,070.00  
7/29/2024Joseph P LyssikatosInsiderSell12,000$26.70$320,400.00  
7/25/2024Samuel KintzCEOSell12,000$24.92$299,040.00  
7/15/2024Anish PatelCOOSell30,978$25.05$775,998.90  
7/15/2024Richard A HeymanDirectorSell1,270$24.80$31,496.00  
7/12/2024Anish PatelCOOSell17,475$25.07$438,098.25  
7/12/2024Benjamin HohlCFOSell3,000$25.07$75,210.00  
6/27/2024Benjamin HohlCFOSell4,250$22.57$95,922.50  
6/25/2024Samuel KintzCEOSell12,000$21.66$259,920.00  
6/6/2024Anish PatelCOOSell1,133$20.06$22,727.98  
5/28/2024Benjamin HohlCFOSell4,250$23.18$98,515.00  
5/28/2024Samuel KintzCEOSell12,000$23.18$278,160.00  
5/16/2024Rishi GuptaDirectorSell1,033,300$22.14$22,877,262.00  
5/14/2024Anish PatelCOOSell1,107$25.00$27,675.00  
5/9/2024Anish PatelCOOSell260$25.06$6,515.60  
5/6/2024Anish PatelCOOSell4,875$22.72$110,760.00  
5/3/2024Benjamin HohlCFOSell1,000$22.50$22,500.00  
4/29/2024Benjamin HohlCFOSell3,250$16.97$55,152.50  
4/29/2024Joseph P. LyssikatosinsiderSell12,000$17.92$215,040.00  
4/25/2024Samuel KintzCEOSell12,000$16.89$202,680.00  
4/15/2024Richard A HeymanDirectorSell1,270$19.99$25,387.30  
4/11/2024Anish PatelCOOSell17,500$25.03$438,025.00  
4/11/2024Benjamin HohlCFOSell14,000$24.72$346,080.00  
4/11/2024Joseph P. LyssikatosinsiderSell30,000$25.04$751,200.00  
4/11/2024Rahul D BallalDirectorSell53,400$23.95$1,278,930.00  
4/11/2024Samuel KintzCEOSell47,709$25.04$1,194,633.36  
4/8/2024Anish PatelCOOSell4,875$18.60$90,675.00  
4/4/2024Rahul D BallalDirectorSell3,485$19.15$66,737.75  
4/1/2024Joseph P. LyssikatosinsiderSell12,000$18.60$223,200.00  
4/1/2024Rahul D BallalDirectorSell3,237$19.08$61,761.96  
3/27/2024Benjamin HohlCFOSell3,250$18.25$59,312.50  
3/25/2024Samuel KintzCEOSell12,000$17.56$210,720.00  
Sell NVDA Now? (Ad)

Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.

Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA).
3/19/2024Richard A HeymanDirectorSell1,270$14.50$18,415.00  
3/6/2024Anish PatelCOOSell4,875$15.64$76,245.00  
2/29/2024Joseph P. LyssikatosinsiderSell12,000$16.42$197,040.00  
2/27/2024Benjamin HohlCFOSell3,250$16.97$55,152.50  
2/15/2024Richard A HeymanDirectorSell1,270$17.42$22,123.40  
2/6/2024Anish PatelCOOSell4,875$15.11$73,661.25  
1/31/20245Am Partners Vi, LlcMajor ShareholderSell500,000$15.00$7,500,000.00  
1/30/2024Richard A HeymanDirectorSell1,270$16.41$20,840.70  
1/29/2024Benjamin HohlCFOSell3,250$15.81$51,382.50  
1/29/2024Joseph P. LyssikatosinsiderSell12,000$15.85$190,200.00  
1/25/2024Samuel KintzCEOSell12,000$15.69$188,280.00  
1/22/2024Anish PatelCOOSell4,875$15.13$73,758.75  
1/2/2024Anish PatelCOOSell11,000$15.00$165,000.00  
1/2/2024Benjamin HohlCFOSell9,383$15.01$140,838.83  
12/26/2023Anish PatelCOOSell102$15.01$1,531.02  
12/26/2023Benjamin HohlCFOSell100$15.00$1,500.00  
12/26/2023Samuel KintzCEOSell12,000$14.64$175,680.00  
12/22/2023Anish PatelCOOSell983$15.03$14,774.49  
12/22/2023Benjamin HohlCFOSell1,030$15.07$15,522.10  
12/22/2023Samuel KintzCEOSell8,175$13.05$106,683.75  
12/21/2023Joseph P. LyssikatosinsiderSell20$13.00$260.00  
12/21/2023Richard A HeymanDirectorSell7$13.00$91.00  
12/20/2023Samuel KintzCEOSell7,779$13.01$101,204.79  
12/19/2023Joseph P. LyssikatosinsiderSell200$13.00$2,600.00  
12/19/2023Richard A HeymanDirectorSell255$13.00$3,315.00  
11/3/2023Joseph P. LyssikatosinsiderSell8,546$13.08$111,781.68  
11/3/2023Samuel KintzCEOSell8,026$13.08$104,980.08  
9/29/2023Joseph P. LyssikatosinsiderSell12,000$13.62$163,440.00  
9/26/20235Am Partners Vi, LlcMajor ShareholderSell197,500$15.00$2,962,500.00  
9/25/2023Samuel KintzCEOSell12,000$13.81$165,720.00  
(Data available from 1/1/2013 forward)

ELVN Insider Trading Activity - Frequently Asked Questions

The list of insiders at Enliven Therapeutics includes 5Am Partners Vi, Llc, Anish Patel, Benjamin Hohl, Joseph P Lyssikatos, Rahul D Ballal, Richard A Heyman, Rishi Gupta, and Samuel Kintz. Learn more on insiders at ELVN.

29.20% of Enliven Therapeutics stock is owned by insiders. Learn more on ELVN's insider holdings.

The following insiders have sold ELVN shares in the last 24 months: 5Am Partners Vi, Llc ($17,502,500.00), Anish Patel ($2,315,446.24), Benjamin Hohl ($1,280,235.66), Joseph P Lyssikatos ($675,688.44), Rahul D Ballal ($1,407,429.71), Richard A Heyman ($198,017.92), Rishi Gupta ($22,877,262.00), and Samuel Kintz ($3,624,943.18).

Insiders have sold a total of 2,713,747 Enliven Therapeutics shares in the last 24 months for a total of $51,736,284.83 sold.

Enliven Therapeutics Key Executives

  • Mr. Samuel S. Kintz M.B.A. (Age 38)
    Co-Founder, CEO, Secretary & Director
    Compensation: $866.41k
  • Dr. Joseph P. Lyssikatos Ph.D. (Age 59)
    Co-Founder & Chief Scientific Officer
    Compensation: $632.67k
  • Dr. Helen Louise Collins M.D. (Age 61)
    Chief Medical Officer
    Compensation: $686.19k
  • Mr. Anish Patel Pharm.D. (Age 43)
    Co-Founder & COO
  • Mr. Benjamin Hohl (Age 34)
    CFO & Head of Corporate Development
    Compensation: $488.5k
    10 recent trades
  • Dr. Galya D. Blachman Esq. (Age 47)
    Ph.D., Chief Legal Officer & Head of Business Development


This page (NASDAQ:ELVN) was last updated on 9/17/2024 by MarketBeat.com Staff
From Our Partners